RETAIN: Risk-Enabled Therapy After Neoadjuvant Chemo for MIBC

By Daniel M. Geynisman, MD - Last Updated: February 23, 2023

Daniel M. Geynisman, MD, Chief of the Division of Genitourinary Medical Oncology, Fox Chase Cancer Center, explains the results and utility of the RETAIN trial for bladder sparing in patients with MIBC.

Post Tags:ASCO GU 2023-Bladder Cancer
Advertisement
Advertisement